

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 938 907 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
01.09.1999 Bulletin 1999/35

(51) Int Cl.⁶: A61M 15/00, B65D 83/04

(21) Application number: 99201271.6

(22) Date of filing: 19.12.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE
Designated Extension States:
AL LT LV RO SI

- Walker, Richard Ian
Ware, Hertfordshire SG12 0DP (GB)
- Davies, Michael Birsha
Ware, Hertfordshire SG12 0DP (GB)
- Farr, Philip William
Ware, Hertfordshire SG12 0DP (GB)

(30) Priority: 03.01.1996 GB 9600044
03.12.1996 GB 9625134

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
96942494.4 / 0 883 414

(74) Representative: Quillin, Helen Kaye et al
Glaxo Wellcome plc
Glaxo Wellcome House,
Berkeley Avenue
Greenford, Middlesex UB6 0NN (GB)

(71) Applicant: GLAXO GROUP LIMITED
Greenford, Middlesex UB6 0NN (GB)

Remarks:

This application was filed on 26 - 04 - 1999 as a
divisional application to the application mentioned
under INID code 62.

(72) Inventors:

- Anderson, Gregor John McLennan
Ware, Hertfordshire SG12 0DP (GB)

(54) Inhalation device

(57) A powder inhalation device comprising a housing containing a pharmacologically active compound, a conduit (8) with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit (6,7) for delivering a dose of the compound to the conduit and baffles (9) arranged within the said conduit to aid disintegration of

powder agglomerates entrained in said airflow. The baffles (9) comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90° to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.




FIG. 5

EP 0 938 907 A1

Descripti n

[0001] This invention relates to an inhalation device by means of which metered doses of medicament in the form of a powder can be dispensed to a user.

[0002] Inhalation devices are known to be used for local administration of drugs to the respiratory tract and lungs of patients. One such device for use with blister packs in which the medicament is held in powder form in the blisters thereof is known as the DISKHALER inhalation device and is described in UK Patent No. 2178965. In use, a fresh blister is indexed to bring it into registration with a use station and then punctured with a puncturing member in two distinct actions to enable the medicament to be inhaled therefrom.

[0003] Another inhalation device described in UK Patent No. 2242134 is for use with peelable medicament packs defining containers for holding the medicament and includes a means for peeling the medicament pack apart to open each container in turn as they are brought into registration with a use station. This device is somewhat complex and contains many components.

[0004] Medicament for administration by inhalation should be of a controlled particle size in order to achieve maximum penetration in to the lungs, preferably in the range of 1 to 10 micrometers in diameter and more preferably 1 to 5 micrometers. Unfortunately, powders in this particle size range, hereinafter referred to as fine powders, for example micronised powders, usually have very poor flow characteristics due to the cohesive forces between the individual particles which make them readily agglomerate together to form bridges which are not readily broken apart to become free flowing. These characteristics create handling and metering difficulties which adversely affect the accurate dispensing of doses of the powder. However, co-pending PCT Patent Application No. EP96.03274 describes how, by careful sizing of fine agglomerated powder, it is possible to make use of the cohesive forces between the particles to create agglomerates of powder which are free flowing. These agglomerates of powder can be easily handled and may be used to conveniently fill devices.

[0005] However, for efficient delivery to the lungs, the powder agglomerates must be broken down before they leave such a device, back into a controlled size.

[0006] It has been found that it is possible to break up powder agglomerates in the airflow as a user inhales by incorporating a series of baffles in the mouthpiece of a powder inhalation device. EP 0 237 507 describes baffles which comprise helical channel portions which give the airflow a rotating, helical pattern of motion.

[0007] However, one disadvantage associated with the baffles described in EP 0 237 507 is that the baffles comprise a number of components rendering the device manufacturing process relatively complicated and expensive.

[0008] GB 2191718 relates to aerosol devices for dispensing nicotine. The nicotine dispensing device has an

impaction means designed to separate the spray allowing the smaller particles and vapour phase to flow around the baffle while the larger particles are removed.

[0009] PCT/EP93/00582 also describes a device comprising baffles which are acting as separators, but if the aerosol contains larger particles in the form of relatively loose agglomerates, these agglomerates are reduced in size if their velocity of impact against the baffles is sufficiently high.

[0010] One disadvantage of the two sets of baffles described in GB 2191718 and PCT/EP93/00582 is the high deposition of powder which can occur due to the baffles extending from the walls of the device at 90° to the direction of airflow. This may result in deposition of the larger agglomerates of powder occurring, which agglomerates could become loose in subsequent inhalations and result in variations in dosage.

[0011] It is an object of the invention to provide a device of the type just described which is simple for a user to operate and which is not unduly complex in its assembly. It is a further object to provide a device which may be filled with powder agglomerates but will deliver powder in a form suitable for administration by inhalation.

[0012] According to the present invention there is provided an inhalation device comprising a housing, an outlet through which a user can inhale, a medicament holder defining at least one pocket for containing a single dose of medicament in the form of a powder, a closure member having at least one closure pad resiliently urged into contact with the medicament holder to close the said at least one pocket, means for moving the pocket into registration with the outlet and means for lifting the closure pad away from the medicament holder to open the pocket when the pocket is brought into registration with the outlet.

[0013] Such a device is simple to operate requiring only one distinct action to enable the medicament to be inhaled therefrom. The device may also comprise relatively few components.

[0014] According to the invention there is also provided a powder inhalation device comprising a housing containing a pharmacologically active compound or medicament, a conduit with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit for delivering a dose of the compound to the conduit and baffles arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow, characterised in that the baffles comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90° to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.

[0015] By use of this arrangement it is possible to provide baffles which are simple to manufacture and provide low deposition of powder, and yet which give good

results in breaking agglomerates down into discrete constituent particles to create a powder of respirable size.

[0016] Preferably the device contains at least 2 plates and more preferably 4 plates.

[0017] Preferably the said plates are inclined at an angle less than 70° to the longitudinal axis of the conduit in the direction of airflow and more preferably the said plates are inclined at an angle in the range of 15° to 50°.

[0018] Suitably the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face of which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.

[0019] An embodiment of the invention is further described below with reference to the accompanying drawings in which:

Figure 1 is a perspective view of an assembled device according to the invention;

Figure 2 is an exploded perspective view of the device of Figure 1 showing the main body components and primary pack;

Figure 3 is an exploded perspective view of the device showing each component in disassembled form;

Figure 4 is a plan view partly in section showing airflow through a preferred embodiment of the invention;

Figure 5 is a perspective view showing airflow through the device shown in Figure 4; and

Figure 6 is a cut away view showing the pocket closure pad held in the raised position

[0020] The device shown in Figures 1 to 3 comprises a body 1 formed of a body base 2 and a body top 3, both of which may be moulded from a plastics material such as acryl-butyl styrene (ABS). Body top 3 is formed with window 4 the purpose of which is described below. The body 1 defines a main housing section adapted to contain a primary pack comprising a dose ring 6 and closure means in the form of a spider 7, and a mouthpiece section 8 forming an outlet through which a user can inhale extending radially from the main housing section. As seen in Figure 2, the mouthpiece section 8 of body base 2 is formed with a plurality of baffles 9 which are explained below.

[0021] A medicament holder in the form of a disk or dose ring 6 comprises an upper surface formed with a plurality of cavities or pockets 10 for containing inhalable

powdered medicament to be dispensed from the device. Each pocket 10 is surrounded by a raised lip (not shown). The dose ring shown is provided with ten pockets 10 which might be suitable for containing ten days' supply of medicament or sufficient medicament for a single course of treatment. It will be understood that the dose ring might have more or fewer pockets depending on the medicament to be contained. Suitable powdered medicaments are, for example, for the treatment of asthma, and include salbutamol, beclomethasone, salmeterol, fluticasone, formoterol, terbutaline, budesonide and flunisolide, and physiologically acceptable salts, solvates and esters or any combination thereof. Preferred medicaments are salbutamol, salbutamol sulphate, salmeterol, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate or solvates thereof and terbutaline sulphate. Other suitable powdered medicaments include antiviral medicaments, for example zanamivir (4-guanidino-Neu-5-Ac-2-en). It will be appreciated by those skilled in the art that the powder medicament, may, if desired, be a combination of two or more active ingredients. A dose may be constituted from the contents of one or more cavities and the size of each cavity will depend on the dose to be delivered. It is to be understood that the medicament powder may consist purely of one or more active ingredients, or there may additionally be a carrier, for example lactose powder.

[0022] The dose ring 6 may be adapted for filling with agglomerated powder in accordance with the method and apparatus described in co-pending PCT Patent Application No. EP96.03274

[0023] The dose ring 6 has a stepped peripheral edge the purpose of which is explained below, and a splined hole in the centre for engagement with the spider 7. The dose ring may also be moulded from a plastics material such as ABS.

[0024] The spider 7 comprises a central ring shaped section 11 from which extend a plurality of resilient radial arms 12, the number of which corresponds to the number of pockets 10 in the dose ring 6. Each radial arm 12 terminates in a pocket closure pad 13. A plurality of short resilient hooked tabs 14 extend axially from the central ring shaped section 11 and are adapted to form a snap-fit with the dose ring 6 by engaging with the splined hole in the centre of the dose ring 6. The spider 7 may be moulded from a plastics material such as polycarbonate or any other engineering plastics which has the required resiliency characteristics. When the spider 7 is assembled to the dose ring 6 to form the dosing unit or primary pack, the hooked tabs 14 tightly engage the splined hole in the dose ring 6 and each pocket closure pad 13 is resiliently urged into contact with a respective raised lip on the upper surface of the dose ring 6 by means of the resilient radial arms 12 in such a position as to cover and seal a respective pocket 10 to prevent loss of medicament from and ingress of moisture into the pocket. The pocket closure pads may be moulded with a smooth flat contact face which seals directly on

the upper surface of the dose ring 6 or raised lip 28 (Figure 6), or alternatively may be provided with a soft sealing material such as a thermoplastic elastomer, eg SANTOPRENE (Bayer), formed on the contact face to improve the sealing characteristics. To manufacture the spider 7 with a different sealing material on the pocket closure pad the spider may be moulded with a channel 15 formed in the upper face of the central ring shaped section 11 and in each radial arm 12, and a small hole (not shown) leading from the end of the channel 15 in each arm 12 through to the underside of the pocket closure pads 13. The sealing material in a molten state may then be made to flow round channel 15 and through the holes to the underside of each of the pocket closure pads 13 to form an integral cushion seal on each pad upon cooling.

[0025] The upper faces of the pocket closure pads 13 may have a number 17 or other indicating means moulded or printed thereon to give an indication as to how many doses of medicament remain in the device as is explained further below.

[0026] An edge of each pocket closure pad 13 is formed with a tab 16 adapted for engagement with a ramp 20 (Figures 4 and 5) integrally formed with body top 3 to effect opening of the pocket as explained below.

[0027] The primary pack fits into the main housing section of the body 1 as shown in Figures 2 and 3 such that axle 21 of body base 2 is located within the hole in the primary pack and the stepped peripheral edge of the dose ring protrudes through two cut away sections on opposite sides of the main housing section. Pawl 24 on body base 2 engages with teeth (not shown) on the underside of dose ring 6 to create a ratchet mechanism which only allows movement of the dose ring in one direction.

[0028] Pockets 10 may be filled with agglomerated powder as described in PCT patent application no. PCT EP96.03274. When so filled, for inhalation therapy it is essential that the largest possible quantity of primary particles inhaled is in the respirable range, that is smaller than 5 microns. In order to aid break-up of any powder agglomerates entrained in the air flow a series of baffles 9 are located in the mouthpiece section 8. As will be explained later, the position of the baffles are important. The baffles can be formed in a single moulding with the body, so affording consistent, controlled and repeatable tolerance. It will be understood that the number and exact dimensions of baffles present will depend on the powder being used and the strength of the forces holding the agglomerates together. For example, it has been found that four baffles achieved the required break up of powder agglomerates of zanamivir. It would be entirely straight forward for a skilled person to experiment with the baffle dimensions to obtain desired flow resistance for a particular powder.

[0029] Figures 4 and 5 show a preferred arrangement of baffles 9 comprising of a plurality of staggered flat plates which extend into the conduit at angles of 30° to

the longitudinal axis of the conduit from opposite sides of the housing. Most of the baffles extend beyond the longitudinal axis of the conduit with the final baffle 25 in the direction of airflow stopping short of the axis. The penultimate baffle 26 in the direction of the airflow has an extended flat face 27 running parallel to the longitudinal axis of the conduit and extending towards the outlet. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.

[0030] A mouthpiece cover 22 is adapted to fit over the mouthpiece section 8 when the device is not in use to prevent contamination of the mouthpiece by dust. The mouthpiece cover has two pins 30 adapted to pass through two slots 23 into the main housing section of body 1 either side of the mouthpiece section 8 to engage the stepped peripheral edge of the dose ring and so lock the primary pack to prevent accidental movement thereof when the device is not in use. To operate the device the user first removes mouthpiece cover 22 thereby unlocking the primary pack. The user then indexes a pocket to bring it into registration with the mouthpiece by holding the stepped peripheral edge of the dose ring where it protrudes through the cut away sections of the main housing section and rotating the dose ring 6 relative to the body 1. The ratchet mechanism described above allows rotation of the primary pack in one direction only. As the primary pack rotates, tab 16 of the next pocket closure pad 13 engages ramp 20 and pocket closure pad 13 is lifted away from the upper surface of the dose ring 6 as the tab rides over the ramp. As the pocket comes into registration with the mouthpiece, the raised lip 28 (Figure 6) surrounding the pocket 10 engages with the sides of the exit channel 29 creating an increased resistance to motion of the dose ring, so giving a clear indication to the user that the dose ring is in position ready for delivery of medicament.

[0031] As the raised lip 28 surrounding the pocket 10 engages with the exit channel 29 the pocket closure pad 13 is in a raised position clear of the upper surface of the dose ring 6 as shown in Figure 6. In this position, pocket closure pad 13 is situated directly beneath window 4 in body top 3 such that the number 17 or other dose indicating means moulded or printed on the upper face of the pocket closure pad 13 is clearly visible through window 4. This allows the user to see how many doses remain in the device.

[0032] The dose of medicament contained in pocket 10 is now ready for delivery. The user inhales through mouthpiece 8. Air is drawn into the device via slots 23 and directed over the open pocket 10 as seen in Figures 4 and 5. As the air flows over pocket 10, medicament powder in the pocket is entrained in the turbulent air flow, drawn through the mouthpiece section 8 and inhaled by the user.

[0033] As seen in Figure 5, baffles 9 are arranged to disrupt the smooth flow of air through the mouthpiece to create additional turbulence, cause the air flow to

change direction several times to cause any agglomerates of powder to collide with the baffles, walls and other agglomerates, and constrict the air flow to increase the flow velocity. The air circulation produces eddy currents in the back waters of the baffles creating further collisions to aid in the break up of the powder agglomerates. This is shown by the arrows representing air flow in Figure 5. All of these effects promote the disintegration of powder agglomerates entrained in the air flow to render the powder in a form suitable for inhalation therapy. The extended flat face 27 running parallel to the longitudinal axis of the conduit attached to the penultimate baffle in the direction of airflow enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.

[0034] After inhalation the user replaces mouthpiece cover 22 to protect and lock the device until the next dose is required to be delivered.

[0035] It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.

plates are inclined at an angle of 30°.

7. A device as claimed in any one of claims 1 to 6, wherein the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face of which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit.
8. A device as claimed in any preceding claim, wherein the medicament is zanamivir.

Claims

1. A powder inhalation device comprising a housing containing a medicament, a conduit with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit for delivering a dose of the compound to the conduit and baffles arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow, wherein the baffles comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90° to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.
2. A device as claimed in claim 1, comprising at least 2 plates.
3. A device as claimed in claim 2, comprising 4 plates.
4. A device as claimed in any one of claims 1 to 3 wherein the said plates are inclined at an angle less than 70° to the longitudinal axis of the conduit in the direction of airflow.
5. A device as claimed in claim 4, wherein the said plates are inclined at an angle in the range of 15° to 50°.
6. A device as claimed in claim 5 wherein the said




FIG. 1





FIG. 2

FIG. 3







FIG. 4






FIG. 6



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 20 1271

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	DE 42 08 880 A (BOEHRINGER INGELHEIM KG) 23 September 1993 * claim 1; figure 3 *	1,2,4-6	A61M15/00 B65D83/04
Y	EP 0 558 879 A (ASTRA AB) 8 September 1993 * claims 11,12 *	1,2,4-6	
A	US 4 907 583 A (WETTERLIN KJELL I L ET AL) 13 March 1990 * column 4, last paragraph; claim 1 *	1	
A	US 3 288 277 A (HALLERBACH) 29 November 1966		
			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</p> <p>A61M A61J B65D</p>
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 31 May 1999	Examiner Villeneuve, J-M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (Pct/01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 20 1271

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-05-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4208880 A	23-09-1993	AU 680191 B	24-07-1997
		AU 3747993 A	21-10-1993
		BR 9306112 A	13-01-1998
		CA 2131544 A,C	30-09-1993
		CZ 9402285 A	18-01-1995
		WO 9318811 A	30-09-1993
		EP 0633792 A	18-01-1995
		FI 944297 A	16-09-1994
		HU 69417 A,B	28-09-1995
		JP 8500743 T	30-01-1996
		NO 943463 A	16-09-1994
		NZ 249846 A	24-02-1997
		PL 171269 B	28-03-1997
		SK 110794 A	08-02-1995
		US 5676130 A	14-10-1997
EP 0558879 A	08-09-1993	AT 167067 T	15-06-1998
		AU 666171 B	01-02-1996
		BR 9306023 A	18-11-1997
		CA 2131157 A	16-09-1993
		CN 1080875 A,B	19-01-1994
		CZ 9402084 A	18-01-1995
		DE 69319100 D	16-07-1998
		DE 69319100 T	28-01-1999
		WO 9317728 A	16-09-1993
		EP 0629136 A	21-12-1994
		ES 2118223 T	16-09-1998
		FI 944034 A	02-09-1994
		GR 3027773 T	30-11-1998
		HU 69090 A,B	28-08-1995
		JP 7508184 T	14-09-1995
		NO 943211 A	30-08-1994
		NZ 249128 A	26-01-1996
		SG 49134 A	18-05-1998
		SK 104994 A	12-04-1995
		US 5533505 A	09-07-1996
		ZA 9301520 A	06-09-1993
US 4907583 A	13-03-1990	SE 453566 B	15-02-1988
		SG 92094 G	17-03-1995
		AT 70720 T	15-01-1992
		AU 601400 B	13-09-1990
		AU 6960487 A	10-09-1987
		CA 1276848 A	27-11-1990
		CY 1798 A	17-02-1995
		DE 3775433 A	06-02-1992

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 20 1271

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-05-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4907583 A		DK 115487 A,B,	08-09-1987
		EG 18100 A	30-06-1993
		EP 0237507 A	16-09-1987
		FI 871000 A,B,	08-09-1987
		GR 88300028 T	18-10-1988
		GR 3003451 T	17-02-1993
		HK 80194 A	19-08-1994
		HR 920761 A	30-04-1995
		IE 60112 B	01-06-1994
		IN 168166 A	16-02-1991
		JP 2113284 C	21-11-1996
		JP 8024715 B	13-03-1996
		JP 62221366 A	29-09-1987
		KR 9607754 B	12-06-1996
		PH 25194 A	27-03-1991
		PT 84421 A,B	01-04-1987
		SE 8601060 A	08-09-1995
		SI 8710341 A,B	28-02-1997
		YU 34187 A	30-04-1989
		ZA 8701346 A	07-09-1988
US 3288277 A	29-11-1966	NONE	

EPO FORM P/459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82